如何利用LI-RADS的LR-M特征提高钆塞酸增强MRI对混合型肝细胞癌-胆管癌的诊断
回顾性分析99例经病理证实的混合型肝细胞癌-胆管癌(cHCC-CCA,33例)或肝细胞癌(HCC,66例)患者的术前钆塞酸增强MRI,评估2017版LI-RADS各LR-M特征诊断cHCC-CCA的敏感度和特异度;靶环状表现敏感度最高(75.8%),任一LR-M特征诊断cHCC-CCA的敏感度为93.9%、特异度为48.5%,约半数HCC也至少出现一个LR-M特征。
要点
- 靶环状表现诊断cHCC-CCA的敏感度最高,为75.8%(95%CI 60.6%, 87.3%)。
- 任一LR-M特征诊断cHCC-CCA的敏感度93.9%、特异度48.5%,约半数HCC也至少有一个LR-M特征。
- 出现三个LR-M特征时诊断准确度最高(80.8%),但敏感度降至54.5%。
核心结论
- 以2017版LI-RADS定义的任一LR-M特征作为判定条件时,多数cHCC-CCA可被正确归为LR-M,但约半数HCC也至少显示一个LR-M特征。
研究设计与样本
- 回顾性研究,纳入术后病理证实的cHCC-CCA 33例和HCC 66例,共99例;两名放射科医师按2017版LI-RADS评估术前钆塞酸增强MRI的LR-M特征,以病理为参考标准,行多因素logistic回归分析。
关键影像表现/征象
- 靶环状表现包括环状动脉期高强化(rim APHE)、周边「廓清」表现和延迟期中心强化。
- cHCC-CCA中31例(93.9%)至少出现一个LR-M特征,HCC中34例(51.5%)至少出现一个LR-M特征。
诊断标准与关键数值
- 靶环状表现诊断cHCC-CCA的敏感度为75.8%(95%CI 60.6%, 87.3%)。
- 任一LR-M特征诊断cHCC-CCA的敏感度为93.9%(95%CI 80.7, 98.9),特异度为48.5%(95%CI 41.9, 51.0)。
- 出现三个LR-M特征诊断cHCC-CCA的准确度最高,为80.8%(95%CI 72.1, 86.1),敏感度为54.5%(95%CI 41.4, 62.5)。
临床应用与阅片要点
- 阅片时可按2017版LI-RADS逐项评估LR-M特征,任一LR-M特征存在即可将多数cHCC-CCA归为LR-M。
- 需注意约半数HCC也至少显示一个LR-M特征,单一LR-M特征对cHCC-CCA的特异度有限。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To investigate the diagnostic accuracy of each LR-M feature defined in version 2017 of the Liver Imaging Reporting and Data System (LI-RADS) and determine the optimal LR-M feature for differentiating combined hepatocellular-cholangiocarcinoma (cHCC-CCA) and hepatocellular carcinoma (HCC) on gadoxetate-enhanced magnetic resonance imaging (MRI).
METHODS: Ninety-nine patients with pathologically proven cHCC-CCA (n = 33) or HCC (n = 66) after surgery were identified. Two radiologists retrospectively assessed preoperative gadoxetate-enhanced MRI for features favoring non-HCC malignancies (LR-M features) according to LI-RADS version 2017. Multivariate logistic regression analysis was performed to determine the independent differential features. The sensitivity and specificity for diagnosing cHCC-CCA were calculated for each LR-M feature.
RESULTS: Targetoid appearance showed the highest sensitivity (75.8%, 95% confidence interval [CI] 60.6%, 87.3%) to correctly identify cHCC-CCA as LR-M. At least one LR-M feature was observed in 31 (93.9%) patients with cHCC-CCA and 34 (51.5%) patients with HCC. The sensitivity and specificity for diagnosing cHCC-CCA using the presence of any one of the LR-M features were 93.9% (95% CI 80.7, 98.9) and 48.5% (95% CI 41.9, 51.0), respectively. The presence of three LR-M features yielded the highest diagnostic accuracy of 80.8% (95% CI 72.1, 86.1) with a reduced sensitivity of 54.5% (95% CI 41.4, 62.5).
CONCLUSION: The majority of cHCC-CCA cases can be properly categorized as LR-M when any one of the LR-M features defined in the LI-RADS version 2017 is used as a determiner. However, approximately half of HCC cases also show at least one LR-M feature.
KEY POINTS: • Targetoid appearance, including rim APHE, peripheral "washout" appearance, and delayed central enhancement, was the LR-M feature that identified cHCC-CCA as a non-HCC malignancy with the highest sensitivity. • Most cHCC-CCA cases can be properly categorized as LR-M when the presence of any one of the LR-M features was used as the determiner. • Approximately half of HCC cases also showed at least one LR-M feature.
引用
- Lee HS, Kim MJ, An C, et al. How to utilize LR-M features of the LI-RADS to improve the diagnosis of combined hepatocellular-cholangiocarcinoma on gadoxetate-enhanced MRI? Eur Radiol. 2018. PMID: 30552477. doi:10.1007/s00330-018-5893-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。